Monoclonal antibody therapy of cancer

The Molecular Basis of Cancer

Volumn , Issue , 2008, Pages 671-678

  Posada, Juan Gonzales ^a   Frankel, Arthur E ^a,b  

^a SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882923662     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-141603703-3.10055-X     Document Type: Chapter

References (85)

1. Kohler G, Milstein C Continuous cultures of fused cells secreting antibody of predetermined specificity. Nature 1975, 256:495.
2. Diamond BA, Yelton DA, Scharff MD Monoclonal antibodies: a new technology for producing serologic reagents. N Engl J Med 1981, 304:1344.
3. Bodey B, Bodey B, Siegel SE, Kaiser HE Genetically engineered monoclonal antibodies for direct anti-neoplastic treatment and cancer cell specific delivery of chemotherapeutic agents. Curr Pharm Design 2000, 6:261.
4. Green LL Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies. J Immunol Methods 1999, 231:11.
5. Cartron G, Watier H, Golay J, Solal-Celigny P From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004, 104:2635.
6. McLaughlin P, Hagemeister FB, Grillo-Lopez AJ Rituximab in indolent lymphoma: the single-agent pivotal trial. Sem Oncol 1999, 26:79.
7. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005, 106:3725.
8. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l Adulte. J Clin Oncol 2005, 23:4117.
9. Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005, 23:7013.
10. Hensel M, Villalobos M, Kornacker M, Krasniqi F, Ho AD Pentostatin/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's macroglobulinemia/lympho-plasmacytic lymphoma. Clin Lymphoma Myeloma 2005, 6:131.
11. Jain AB, Marcos A, Pokharna R, Shapiro R, Fontes PA, Marsh W, Mohanka R, Fung JJ Rituximab (chimeric anti-CD20 antibody) for posttransplant lymphoproliferative disorder after solid organ transplantation in adults: long-term experience from a single center. Transplantation 2005, 80:1692.
12. Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt's and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 2006, 106:1569.
13. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005, 23:4079.
14. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgRIIIa gene. Blood 2002, 99:754.
15. Maloney DG Concepts in radiotherapy and immunotherapy: anti-CD20 mechanisms of action and targets. Semin Oncol 2005, 32(Suppl 1):S19-S26.
16. Bohen SP, Troyanskaya OG, Alter O, Warnke R, Botstein D, Brown PO, Levy R Variation in gene expression patterns in follicular lymphoma and the response to rituximab. Proc Natl Acad Sci U S A 2003, 100:1926.
17. Kimby E Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005, 31:456.
18. Domagala A, Purpisz M CD52 antigen-a review. Med Sci Monitor 2001, 7:325.
19. Waldmann H, Hale G CAMPATH: from concept to clinic. Philos Trans R Soc Lund B Biol Sci 2005, 360:1707.
20. Faderl S, Coutre S, Byrd JC, et al. The evolving role of alemtuzumab in management of patients with CLL. Leukemia 2005, 19:2147.
21. Pawson R, Dyer MJ, Barge R, et al. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J Clin Oncol 1997, 15:2667.
22. Thursky KA, Worth LJ, Seymour JF, et al. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab. Br J Haematol 2006, 132:3.
23. Nahta R, Esteva FJ Herceptin: mechanisms of action and resistance. Cancer Lett 2006, 232:123.
24. Yakes FM, Chinratanalab W, Ritter CA, et al. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1 and antitumor action. Cancer Res 2002, 62:4132.
25. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005, 23:4265.
26. Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005, 23:3676.
27. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353:1673.
28. Tan-Chiu E, Yothers G, Romond E, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005, 23:7811.
29. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997, 57:4593.
30. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003, 349:427.
31. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335.
32. Kabbinavar FF, Hambleton J, Mass RD, et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005, 23:3706.
33. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005, 23:3502.
34. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004, 22:2184.
35. Mendelsohn J, Baselga J Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003, 21:2787.
36. Italiano A.Targeting the epidermal growth factor receptor in colorectal cancer: advances and controversies. Oncology 70:161.
37. Personeni N, Hendlisz A, Gallez J, et al. Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer. Semin Oncol 2005, 32(Suppl 9):S59-S62.
38. Lievre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006, 66:3992.
39. Luwor RB, Lu Y, Li X, et al. The anti-epidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression. Oncogene 2005, 24:4433.
40. Saltz LB, Meropol NJ, Loehrer PJ Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004, 22:1201.
41. Cunningham D, Humblet Y, Siena S Cetuximab monoclonal and cetuximab plus irinotecan in irniotecan-refractory metastatic colorectal cancer. N Engl J Med 2004, 351:337.
42. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354:567.
43. Xiong HQ, Rosenberg A, LoBuglio A Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial. J Clin Oncol 2004, 22:2610.
44. Laux I, Jain A, Singh S, Agus DB Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies. Br J Cancer 2006, 94:85.
45. Fenton C, Perry CM Spotlight on gemtuzumab ozogamicin in acute myeloid leukaemia. BioDrugs 2006, 20:137.
46. Walter RB, Raden BW, Kamikura DM, Cooper JA, Bernstein ID Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity. Blood 2005, 105:1295.
47. Walter RB, Raden BW, Cronk MR, et al. The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin. Blood 2004, 103:4276.
48. Larson RA, Siervers EL, Stadtmauer EA, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 2005, 104:1442.
49. Amadori S, Suciu S, Stasi R, et al. Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups. Leukemia 2005, 19:1768.
50. Saviola A, Luppi M, Potenza L, et al. Late occurrence of hepatic veno-occlusive disease following gemtuzumab ozogamicin: successful treatment with defibrotide. Br J Haematol 2003, 123:752.
51. Dillman RO Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies. Clin Exp Med 2006, 6:1.
52. Emmanouilides C, Witzig TE, Gordon LI, Vo K, Wiseman GA, Flinn IW, Darif M, Schilder RJ, Molina A Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated non-Hodgkin's lymphoma. Leuk Lymphoma 2006, 47:629.
53. Gordon LI, Molina A, Witzig T, Emmanouilides C, Raubtischek A, Darif M, Schilder RJ, Wiseman G, White CA. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood 103:4429 .
54. Witzig TE Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: a new treatment approach for B-cell non-Hodgkin's lymphoma. Drugs Today 2004, 40:111.
55. Wahl RH Tositumomab and 131I therapy in non-Hodgkin's lymphoma. J Nucl Med 2005, 46:128S-140S.
56. Fisher RI, Kaminski MS, Wahl RL, Knox SJ, Zelenetz AD, Vose JM, Leonard JP, Kroll S, Goldsmith SJ, Coleman M Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol 2005, 23:7565.
57. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005, 352:441.
58. Leonard JP, Coleman M, Kostakoglu L, et al. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I131 tositumomab for untreated follicular lymphoma. J Clin Oncol 2005, 23:5696.
59. Kaminski MS, Radford JA, Gregory SA, et al. Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab. J Clin Oncol 2005, 23:7985.
60. Body JJ, Facon T, Coleman RE, et al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006, 12:1221.
61. Reardon DA, Akabani G, Coleman RE, et al. Salvage radioimmunotherapy with murine iodine-131-labeled anti-tenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol 2006, 24:115.
62. Pagel JM, Appelbaum FR, Eary JF, et al. 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood 2006, 107:2184.
63. Ribas A, Camacho LH, Lopez-Berestein G, et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol 2005, 23:8968.
64. Blansfield JA, Beck KE, Tran K, et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother 2005, 28:593.
65. Linden O, Hindorf C, Cavallin-Stahl E, et al. Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab. Clin Cancer Res 2005, 11:5215.
66. Czuczman MS, Thall A, Witzig TE, et al. Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol 2005, 23:4390.
67. Leonard JP, Coleman M, Ketas J, et al. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 2005, 23:5044.
68. Agus DB, Gordon MS, Taylor C, et al. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 2005, 23:2534.
69. Walshe JM, Danduluri N, Berman AW, et al. A phase II trial of trastuzumab and pertuzumab in patients with HER2-overexpressing locally advanced and metastatic breast cancer. Clin Breast Cancer 2006, 6:535.
70. Bander NH, Milowsky MI, Nanus DM, et al. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 2005, 23:4591.
71. Milowsky MI, Nanus DM, Kostakoglu L, et al. Phase I trial of Yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol 2004, 22:2522.
72. Chatal JF, Campion L, Kraeber-Bodere F, et al. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French endocrine tumor group. J Clin Oncol 2006, 24:1705.
73. Sharma K, Janik J, O'Mahony D, et al. A phase II study of the efficacy and toxicity of alemtuzumab for the therapy of human T cell lymphotrophic virus-1 (HTLV-1)-associated adult T-cell leukemia/lymphoma (ATL). J Clin Oncol 2006, 24(Suppl 18):108s.
74. Strohlein MA, Gruetzner KU, Tarabichi A, et al. Efficacy of intraperitoneal treatment with the trifunctional antibody catumaxomab in patients with GI-tract cancer and peritoneal carcinomatosis: a matched-pair analysis. J Clin Oncol 2006, 24(Suppl 18):111s.
75. Perez-Soler R, Zou Y, Li T, Tornos C, Ling Y Topical vitamin K3 (Vit K3, menadione) prevents erlotinib and cetuximab-induced EGFR inhibition in the skin. J Clin Oncol 2006, 24(Suppl 18):129s.
76. Small E, Higano C, Tchekmedyian N, et al. Randomized phase II study comparing 4 monthly doses of ipilimumab (MDX-010) as a single agent or in combination with a single dose of docetaxel in patients with hormone-refractory prostate cancer. J Clin Oncol 2006, 24(Suppl 18):243s.
77. Nicodemus CF, Berek JS, Schultes BC, et al. Final follow-up survey of the randomized Pbo-controlled study of oregovomab (Ov) as a consolidation treatment for advanced ovarian cancer (OC): insights into surveillance approaches. J Clin Oncol 2006, 24(Suppl 18):275s.
78. Drucker A, Virik K, Skedgel C, et al. The cost burden of trastuzumab and bevacizumab monoclonal antibody therapy in solid tumors: can we afford it?. J Clin Oncol 2006, 24(Suppl 18):312s.
79. Vonderheide RH, Flaherty KT, Khalil M, et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 2006, 24(Suppl 18):101s.
80. Sebastian M, Schuette W, Schneller F, et al. Treatment of malignant pleural effusion with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3): results of a phase I/II study. J Clin Oncol 2006, 24(Suppl 18):112s.
81. Kuenen B, Witteveen E, Ruijter R, et al. A phase I study of IMC-11F8, a fully human anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody in patients with solid tumors. Interim results. J Clin Oncol 2006, 24(Suppl 18):126s.
82. Kreitman RJ, Squires DR, Stetler-Stevenson M, et al. Phase I trial of recombinant immunotoxin RFB4(dsFv) -PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol 2005, 23:6719.
83. Kim SJ, Park Y, Hong HJ Antibody engineering for the development of therapeutic antibodies. Mol Cells 2005, 20:17.
84. Bode U, Buchen S, Janssen G, et al. Results of a phase II trial of h-R3 monoclonal antibody (nimotuzumab) in the treatment of resistant or relapsed high-grade gliomas in children and adolescents. J Clin Oncol 2006, 24(Suppl 18):63s.
85. Allan DGP Nimotuzumab: evidence of clinical benefit without rash. Oncologist 2005, 10:760.